BSE filing, NSE: EPIGRAL. Summary written from the filing by ALFA Finder's alert engine.
Epigral Ltd: key numbers
- Share price
- ₹895.40
- Market cap
- ₹3,863 Cr
- Revenue (annual)
- ₹2,527 Cr
- Net profit (annual)
- ₹332.0 Cr
- P/E (TTM)
- 14.2×Sector 34.1×
- Promoter holding
- 68.83%+0.00% QoQ
- FII holding
- 0.99%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Epigral Ltd
All →Epigral Board Meeting Date
Epigral schedules a board meeting on November 2, 2026 to approve unaudited Q2 and half-year results ended September 30, 2026. The notice is issued for shareholder information.
Epigral Other Announcement
Epigral Limited submitted a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, regarding security dematerialization for the quarter ended September 30, 2026.
Epigral Earnings Call Transcript: Key Takeaways
Epigral reported 15% revenue growth and 25% EBITDA margins despite Red Sea logistical disruptions. Management is pivoting toward high-value downstream specialty chemicals like Epoxy resins to reduce commodity exposure.
- Call
- Guides 20% growth
Epigral Capacity Expansion: ₹650 Cr Investment
Epigral Ltd will invest ₹650 Crore to add 1,25,000 TPA of Epoxy Resin & Formulations capacity at its Dahej facility, expected by H2 FY2028.
- Value
- ₹650.0 Cr
- Execution
- By H2 FY2028
Epigral Investor Presentation: Key Takeaways
Epigral reported 15% YoY revenue growth and 25% PAT growth for Q1FY27. Strategy focuses on diversifying into high-value derivatives and specialty chemicals with significant capex for Epoxy Resin and Multi-Purpose plants.
- Call
- Guides 70% growth
Epigral Results Update
Epigral reported Q1FY27 PAT of ₹99 Crore, a 25% YoY increase. The company plans ₹600 Crore capex for Epoxy Resin and Multi-Purpose Plant.
- Value
- ₹600.0 Cr
- Execution
- H2FY28
Other board meeting date announcements
All →Indowind Energy Board Meeting Date
Indowind Energy scheduled a board meeting on 5 Nov 2026 to approve Q1 FY27 unaudited results. The trading window remains closed until 48 hours post-approval.
Dhunseri Ventures Board Meeting Date
Dhunseri Ventures Ltd intimated that its Board will meet on 6 November 2026, inter alia to approve Q2 FY27 results. The trading window stays closed until 8 November 2026.
CESC Board Meeting Date
CESC Ltd scheduled its Board Meeting for 5 Nov 2026 to consider Q2/H1 FY27 unaudited results. No financial figures or decisions are reported in this advance intimation.
Genpharmasec Board Meeting Date
Genpharmasec Ltd will hold a Board meeting on 03 Nov 2026. Agenda includes proposing approval of Q2/H1 FY27 unaudited results.
Hexa Tradex Board Meeting Date
Hexa Tradex scheduled its board meeting for November 5, 2026, to approve Q2 FY27 unaudited financial results. Trading window closes until 48 hours post-disclosure.
Ampvolts Board Meeting Date
Ampvolts Ltd has scheduled its Board meeting for November 6, 2026, to approve unaudited Q2/H1 FY27 results. No financial figures are disclosed in this prior intimation.